BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...
BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

Politics, Policy & Law When Janet Woodcock moves into the FDA commissioner’s office next week, she will take charge, at least on an acting basis, of an agency that has been pummeled for months. President...
BioCentury | Jan 15, 2021
Politics, Policy & Law

Biden signals new path for Warp Speed, names Kessler to replace Slaoui

President-elect Joe Biden will appoint former FDA Commissioner David Kessler to replace Moncef Slaoui as scientific leader of the U.S. government’s COVID-19 countermeasures development program.  In a plan released Friday, Biden, who Thursday called the...
BioCentury | Jan 7, 2021
Deals

Jan. 6 Quick Takes:  Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed...
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

U.S. secures an additional 100M doses of Pfizer-BioNTech vaccinePfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) entered an agreement to supply the U.S. government with an additional 100 million doses of BNT162b2 for $1.95 billion, bringing...
BioCentury | Dec 11, 2020
Product Development

AZ and Oxford paper spotlights the swerves on the road to pooled vaccine efficacy readout

The first peer-reviewed paper on pivotal data from a COVID-19 vaccine details the unplanned protocol shifts complicating the pooled efficacy analysis of AstraZeneca and Oxford’s AZD1222. The Lancet study, published Tuesday, contains the efficacy and...
BioCentury | Dec 8, 2020
Management Tracks

Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets

Oncolytic virus company Candel has bolstered its executive team with a quartet of industry veterans headlined by new CEO Paul Peter Tak, a biotech entrepreneur and GSK veteran who plans to raise venture money to...
BioCentury | Dec 5, 2020
Product Development

The vaccine is here. Three questions about what happens next

The COVID-19 vaccine rollout is starting in the U.K., and is on the doorstep in the U.S. and Europe, building to a collective huge sigh of relief. The efficacy, at least for the first two,...
BioCentury | Nov 26, 2020
Product Development

U.S. government spending on Abbott BinaxNOW outstrips other rapid COVID-19 tests: Data Byte

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test. A fact sheet released by HHS Tuesday showed the U.S. federal government has spent $760 million on the antigen test from Abbott...
BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

Legend Biotech Corp. (NASDAQ:LEGN) appointed Ye “Sally” Wang as chairwoman and promoted Ying Huang to CEO from CFO. Wang, who was already a member of Legend’s board, is president, COO and a director of...
Items per page:
1 - 10 of 557